Historically they have paid around 70% to 80% & management has already stated they will be returning to these levels over the next 2 years. The balance sheet is clear of debt & cash flow is strong without the sale of treasury shares.
Earnings will be boosted by increased revenues from the Life Sciences Division & management has stated the fact that this growth has been based upon acquisition's over the past 3 years (look at the 10K.)
This is a Mergent Dividend Achiever & not a growth stock although it could achieve growth status through the life sciences division.
Day traders are encouraged to short so I can accumulate on dips & hold for the next 10 years!